Trial Profile
Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Somatostatins (Primary)
- Indications Primitive neuroectodermal tumours
- Focus Therapeutic Use
- 07 Oct 2019 Status changed from recruiting to discontinued.
- 12 Apr 2013 New trial record